Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Tue, 02.04.2024
ABIVAX
Abivax reports 2023 financial results and operational update
Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market
Sufficient funds to finance operations into Q4 2025, including through the announcement of t [ … ]
Tue, 13.02.2024
ABIVAX
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
PARIS, France, February 13, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechno [ … ]
Wed, 07.02.2024
ABIVAX
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune respon [ … ]
Fri, 02.02.2024
ABIVAX
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December 2023 and cleared to proceed
In alignment with FDA feedback, Abivax to modify CD trial design and conduct dose ranging Phase 2b clinical trial
Start of pati [ … ]
Wed, 24.01.2024
ABIVAX
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
PARIS, France, January 24, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology c [ … ]
Mon, 22.01.2024
ABIVAX
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC)
Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC h [ … ]
Thu, 04.01.2024
ABIVAX
Abivax 2024 Financial Communication Calendar
PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chro [ … ]
Tue, 21.11.2023
ABIVAX
Abivax announces the resumption of its liquidity contract
Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in pati [ … ]
Tue, 14.11.2023
ABIVAX
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the imm [ … ]
Tue, 24.10.2023
ABIVAX
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PARIS, France, October 24, 2023 – 10:05 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to mod [ … ]